Monograph
C03CA01 - Furosemide |
Propably not porphyrinogenic |
PNP |
Rationale
(CAVE: under revision)Sulfonamide derivative. Conflicting references, but non-metabolism as well as clinical observations point to non-porphyrinogenicity.
Chemical description
Sulfonamide derivative.
Therapeutic characteristics
Shortacting loop-diuretic.
Metabolism and pharmacokinetics
Primarily excreted by filtration and secretion as unchanged drug. Some liver metabolism may occur. The glucuronide is the most significant metabolite. Non-porphyrinogenic metabolism.
Personal communication
Thunell, patient report (n=2): tolerated. Andersson, patient report (n=9): tolerated.
Published experience
Two non-English publications seem to involve uneventful exposure of two acute porphyria patients (Lopes Montes 2004, Moeschlin 1975).
IPNet drug reports
Uneventful use reported in 47 patients with acute porphyria.
References
| # |
Citation details |
PMID |
|---|
| * | Scientific articles |
| 1. |
Moeschlin S, 1975. PMID 56031.
|
56031 |
| 2. |
2004. PMID 15219077.
Lopes Montes A et al. |
15219077 |
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
